Article No
AG-20A-0035-C100
anti-IDO1 (human), mAb (ID 177)
anti-IDO1 (human), mAb (ID 177)
Antibodies Primary
Specifications
| Application | ELISA, IHC, WB |
| Article No | AG-20A-0035-C100 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT |
| Clone | ID 177 |
| Clone Type | monoclonal |
| Concentration | 1 mg/ml |
| Conjugation | Unconjugated |
| Description | anti-IDO1 (human), mAb (ID 177) |
| Supplier | Adipogen Life Sciences |
| Entrez Gene ID | 3620 |
| Format | Liquid |
| Gene Symbol | IDO1 |
| Immunogen | Recombinant human IDO1. |
| Isotype | IgG1 k |
| Notes | IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system's ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.|Monoclonal Antibody. Recognizes human IDO. Detects a band of ~45kDa by Western blot. Other species not tested. Isotype: Mouse IgG1kappa. Clone: ID 177. Applications: ELISA, IHC, WB. Liquid. 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives. IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders. |
| Alias Names | Indoleamine 2,3-dioxygenase; INDO |
| Product Type | Antibodies Primary |
| Research area | Metabolism |
| Shipping Information | BLUE ICE |
| Size | 100 ug |
| Source / Host | mouse |
| Species Reactivity | human |
| Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Storage | -20°C, 4°C |
| Substrate / Buffer | Liquid. 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives. |
| Technical Specifications | Monoclonal Antibody. Recognizes human IDO. Detects a band of ~45kDa by Western blot. Other species not tested. Isotype: Mouse IgG1kappa. Clone: ID 177. Applications: ELISA, IHC, WB. Liquid. 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives. IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders. |
| UniProt Number | P14902 |
| Product Page Updated | 2024-02-01T08:25:01.492Z |
